Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Diabetes drug metformin tested in kidney patients – could change treatment guidelines

NCT ID NCT02710448

First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 35 times

Summary

This study looked at whether the common diabetes drug metformin can be used safely in people with kidney failure. Researchers gave increasing doses of metformin to 82 diabetic patients with various stages of kidney disease and measured drug levels in their red blood cells. The goal was to see if these levels stayed within a safe range, which could help guide future use of metformin in this group.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Service d'Endocrinologie, Maladies Métaboliques et Nutrition

    Amiens, 80054, France

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Metformin

What this could lead to

If successful, this could help doctors safely prescribe metformin to diabetic patients with kidney disease, expanding treatment options.

What could go wrong

This is a small, early-phase study (82 participants) focused on drug levels, not long-term safety or outcomes. Results may not apply to all patients.

Conditions

The condition(s) this trial relates to.

diabetic kidney disease kidney failure type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.